The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients
Status:
Completed
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
Metformin, a traditional antidiabetic medication, exerts glucose lowering effects by
activating AMP-activated protein kinase (AMPK), a critical enzyme involved in the lipid and
glucose metabolism. In addition to the antidiabetic effect, metformin has been shown to
inhibit Lipopolysaccharide-Induced Inflammation (LPS)-induced inflammation by suppress NF-κB
production, which is also regulated by AMPK. These regulatory effects of AMPK on the
inflammation, immune and fibroblast-like synovial cells have prompted the investigation on
the effects of metformin on rheumatoid arthritis.